A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Endometrial cancer; Gynaecological cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 04 Jun 2024 Results (As of November 09, 2023, n=170) assessing the efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced EC presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 13 Sep 2022 Results(As of February 18, 2022, n=29 ) assessing efficacy and safety of TQB2450 injection or combined with anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial cancer .presented at the 47th European Society for Medical Oncology Congress.
- 17 Aug 2021 Planned number of patients changed from 166 to 196.